Professor Gregory is not only enthusiastic about his own career, but also personally introduced the senior management of GlaxoSmithKline to Chen Shuqin.
No one knows the process of the tripartite negotiations, but in the end several agreements were reached.
1. Pumpkin Vine Pharmaceuticals officially invited Professor Gregory to become a partner in Helicobacter pylori research.
Professor Gregory is a spokesperson for GlaxoSmithKline. His formal joining also means the participation of GlaxoSmithKline. Now we are all one family with a community of interests.
2. Pumpkin Vine Pharmaceuticals has officially authorized GlaxoSmithKline to obtain patents for three drugs: omeprazole, clarithromycin, and potassium citrate bismuth. The company can produce the drugs on its own. Its business scope covers the whole of Europe and Africa, and the patent licensing fee is 4.2% of sales.
Don't underestimate this 0.8% profit concession. It involves tens of millions of dollars, and even hundreds of millions of dollars in the future. This makes the top management of GlaxoSmithKline very satisfied.
Capitalists only care about money, and only money can impress them.
3. GlaxoSmithKline supports the Helicobacter pylori research in its application for a Nobel Prize in Medicine in the future and is willing to provide full public relations assistance (public relations expenses will be covered by Pumpkin Vine).
4. GlaxoSmithKline is preparing to sell the Margaret Hospital Hong Kong to Pumpkin Vine Hong Kong Company and will no longer retain shares.
The acquisition of the hospital was an unexpected gain, and Chen Shuqin seized the opportunity.
In the next few days, Chen Shuqin's negotiations with two other international pharmaceutical giants were very successful.
Because this is an unequal negotiation in itself, Xiangjiang Pumpkin Vine Pharmaceutical Company has a lot of room to maneuver.
And from the perspective of business negotiations, introducing multiple pharmaceutical companies will create a multi-party competition and allow negotiations to be completed as quickly as possible.
In order to avoid granting too many patents to pharmaceutical companies, which would cause unnecessary competition and trouble, and to allow pharmaceutical companies that have obtained patents to taste the sweetness of monopoly, the pumpkin vine patent was only granted to three pharmaceutical companies this time.
The United States' Huiduan Pharmaceutical obtained the patent rights in the Americas, GlaxoSmithKline obtained the patent rights in Europe and Africa, and Japan's Takeda Pharmaceutical obtained the patent rights in Asia and Oceania (excluding mainland China and Hong Kong).
Royalties will be 4.6% of sales, up from 5% previously. (The agreement with GlaxoSmithKline is confidential.)
A slight concession was made here, but there were also gains. Pumpkin Vine signed a strategic cooperation agreement with the three largest pharmaceutical companies in the world.
If Pumpkin Vine Pharmaceuticals has any new drugs in the future, under the same conditions, the patents will be given priority to Pfizer, GlaxoSmithKline, and Takeda Pharmaceuticals.
At the same time, the three pharmaceutical companies promised that when Pumpkin Vine's new drug was to be exported, they would handle the public relations with the drug regulatory authorities of the country where it was located.
We will also fully support the Nobel Prize public relations for the Helicobacter pylori topic.
This is beneficial to everyone. As long as this topic wins the Nobel Prize, the patent will be more valuable, and the public will be more willing to believe in this Nobel Prize-winning quadruple therapy.
With the support of these three giants, winning the Nobel Prize is no longer a problem. I dare not say it is 100%, but the success rate is almost 99%.
After finishing a series of business negotiations in London, Chen Shuqin returned to China and flew directly from England to the mainland.
A large delegation also came to the mainland with Chen Shuqin.
These include Mr. Gregory, director of the gastroenterology department at Wellington Hospital and professor at the University of Oxford Medical School, and Mr. Chris Grayling, deputy general manager of GlaxoSmithKline.
Professor Gregory came here for the China-UK-Hong Kong Tripartite Laboratory. This is a major event that concerns him and Chen Chun's joint bid for the Nobel Prize in Medicine, so he must personally oversee it.
GlaxoSmithKline's arrival was mainly due to the sale of the Hong Kong Margaret Hospital.
Chen Xia is really lucky to have the halo of the protagonist.
It happened to be 1984, when China and Britain signed an agreement on the return of Hong Kong. People's hearts were unstable, and what followed was a stock market crash, a property market collapse, and the economy began to enter a state of crisis.
The English are very smart. Since Hong Kong will no longer be their territory, they will make trouble wherever they need to and take advantage of opportunities to arbitrage.
What was reflected in the market was not only the withdrawal of a large amount of funds from the stock and property markets, but also the large-scale withdrawal of British capital. Ultimately, they had no confidence in Hong Kong's return to China.
Coincidentally, as a member of the British capital, the senior management of GlaxoSmithKline was also preparing to liquidate and withdraw from its assets in Hong Kong, including the Princess Margaret Hospital.
Margaret Hospital was established in 1937 and is located in the southwest of Hong Kong Island. It is a private comprehensive hospital and ranks third among all hospitals in Hong Kong. It has 1,000 beds and all departments are fully equipped.
But the embarrassing thing about this hospital is that it ranks third, neither higher nor lower.
It is not a top hospital in Hong Kong, and cannot attract too many top wealthy people to seek medical treatment, so it cannot receive donations from these wealthy people.
The high fees charged by private hospitals mean that most Hong Kong citizens will not go to Margaret Hospital for treatment.
Therefore, although the hospital has not made a loss after operating for so many years, it has not been able to generate any profit.
For capitalists, not being able to make money is the original sin, it is like chicken ribs, tasteless to eat and a pity to throw away.
However, due to political needs, GlaxoSmithKline had been maintaining the normal operation of the Margaret Hospital, and of course it had no further investment, and had always been the third largest company, with no desires or ambitions.
Now that British capital is withdrawing, GlaxoSmithKline is also about to follow suit, so they are interested in selling the Margaret Hospital and have also contacted some Hong Kong Chinese capital.
However, hospitals are non-profit organizations and do not generate large profits. In addition, large sums of money are required to fund the hospital's scientific research and upgrade its equipment.
Those wealthy people in Hong Kong are not very interested. For those vampires, the real estate industry is a quick way to make money. Who is interested in the thankless task of managing people's livelihood?
The key point is that the land of Margaret Hospital is for medical use, and the law stipulates that it cannot be converted into commercial and residential use. So what is the point of buying it for the hospital?
In this way, the hospital has been unable to find anyone to take over.
It just so happened that Pumpkin Vine Pharmaceuticals had an idea, and GlaxoSmithKline could just shirk the responsibility, so the two parties immediately hit it off.
But this is a large hospital after all. If we say we are going to sell it to you, many conditions need to be negotiated, not just the transfer fee.
Since GlaxoSmithKline has decided to form an alliance with Pumpkin Vine, it certainly needs to gain the favor of Chen Xia, the boss behind the scenes, and also see if there are other areas for cooperation?
So Chris Grayling, the manager of GlaxoSmithKline, also came to China.
Continue read on readnovelmtl.com
